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A reduction in the cellular levels of the cyclin kinase inhibitor p27kip1 is frequently found in many human can-
cers and correlates directly with patient prognosis. In this work, we identify argyrin A, a cyclical peptide
derived from the myxobacteriumArchangium gephyra, as a potent antitumoral drug. All antitumoral activities
of argyrin A depend on the prevention of p27kip1 destruction, as loss of p27kip1 expression confers resistance
to this compound. We find that argyrin A exerts its effects through a potent inhibition of the proteasome. By
comparing the cellular responses exerted by argyrin A with siRNA-mediated knockdown of proteasomal sub-
units, we find that the biological effects of proteasome inhibition per se depend on the expression of p27kip1.INTRODUCTION
The cyclin kinase inhibitor p27kip1 is one of the most frequently
dysregulated tumor suppressor proteins in human cancers. Its
expression levels closely correlate with the overall prognosis of
the affected patient (Porter et al., 2006). In strong contrast to
other tumor suppressor proteins, the p27kip1 genomic locus is
rarely mutated in cancer cells, indicating that transcriptional
and posttranscriptional mechanisms are responsible for the re-
duction of p27kip1 expression (Philipp-Staheli et al., 2001). Since
the discovery of skp2 as the essential F box protein that as part
of the SCF E3 ubiquitin ligase controls p27kip1 stability, severalexamples of an inverse correlation between skp2 and p27kip1 ex-
pression in different tumors have been published. Some studies
have even shown that tissues from tumors that express low
levels of p27kip1, i.e., colon carcinoma, mantle cell lymphoma,
small-cell lung cancer, and others, also display an increase in
p27kip1-degradatory activity (Ben-Izhak et al., 2003; Osoegawa
et al., 2004). Moreover, a number of molecular treatments like
the inhibition of the EGF or ErbB2 receptors, either by inhibitory
antibodies or small-molecule drugs, result in increased expres-
sion of the p27kip1 protein (Lenferink et al., 2000). Together, these
findings suggest that an increase in p27kip1 expression levels
should prevent tumor cell proliferation. To test this possibility,SIGNIFICANCE
In this work, we identify an antitumoral drug, argyrin A, which acts by stabilizing the cyclin kinase inhibitor p27kip1. Due to
increased turnover, p27kip1 is not sufficiently expressed in many human cancers, and therefore targeting the p27kip1 degra-
dation machinery might prove beneficial in the treatment of a variety of human malignancies. We also show that p27kip1 be-
longs to a group of critical substrates that mediate the biological effects of proteasome inhibition. In addition to identifying
a p27kip1-stabilizing compound, our work improves the understanding of proteasome-regulated processes under normal
and pathophysiological conditions.Cancer Cell 14, 23–35, July 2008 ª2008 Elsevier Inc. 23
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Pharmacological Targeting of p27kip1we recently created a mouse model in which the proteolytic turn-
over of p27kip1 is partly blocked through a mutation in a p27kip1
phosphorylation site that is critical for ubiquitin-dependent pro-
teasomal turnover (p27T187A) (Malek et al., 2001). When these
mice are challenged with a carcinogen (ENU), they develop a
variety of tumors with no apparent difference in tumor spectrum
compared to wild-type mice. Importantly, however, expression
of p27T187A significantly reduces the number of intestinal ade-
nomatous polyps that progress to invasive carcinomas (Timmer-
beul et al., 2006). This study therefore showed that prevent-
ing p27kip1 degradation could be beneficial in the treatment or
prevention of intestinal cancer.
Based on these studies, we set out to identify substances
that would reduce or block p27kip1 turnover, thereby allowing
re-expression of the protein in tumor tissues.
RESULTS
A Cell-Based Screening Assay Identifies Argyrin A as
a Compound that Prevents p27kip1 Degradation
To identify substances that lead to an increase in the expression
levels of p27kip1, we generated a high-throughput assay system
based on the stable expression of a p27kip1-GFP fusion protein in
human cells (see Experimental Procedures for details). One of
the substances that exerted the strongest increase in fluores-
cence was identified as argyrin A, a cyclical peptide that had
originally been identified as a metabolic product derived from
the myxobacterium Archangium gephyra (Sasse et al., 2002)
(Figure 1A). The time-course experiment displayed in Figure 1B
shows that argyrin A induced an increase in cellular p27kip1 levels
in HCT116, SW480, and HeLa cells. To determine whether the
argyrin A-induced change in p27kip1 expression levels was due
to an increase in its stability, we measured the half-life of
p27kip1 in HeLa and SW480 cells in the presence and absence
of argyrin A. Figure 1C shows a quantification of the expression
levels of p27kip1 compared to actin in cycloheximide-treated
cells that were incubated with argyrin A or left untreated. While
p27kip1 had a half-life of 4 hr (SW480) or 9 hr (HeLa) in untreated
cells, addition of argyrin A blocked the turnover of p27kip1
completely. These results indicate that argyrin A treatment
results in an increase in endogenous p27kip1 levels by preventing
the turnover of the protein.
As all known p27kip1 turnover mechanisms involve proteolytic
destruction of the protein by the 20S proteasome (Montagnoli
et al., 1999; Sutterluty et al., 1999), we next measured the activity
of purified human proteasomes after incubation with increasing
amounts of argyrin A. Figure 2A shows that incubation of purified
human 20S proteasome with argyrin A in vitro led to a dose-de-
pendent inhibition of the caspase-, trypsin- and chymotrypsin-
like proteasome activities. Importantly, the extent of proteasome
inhibition by argyrin A was comparable to that measured with the
clinically used proteasome inhibitor bortezomib (Velcade). In
agreement with the ability of argyrin A to inhibit the proteasome,
we found that other well-known proteasome substrates, namely
p53, p21, Bax, and NF-kB, also accumulated in response to
argyrin A treatment (Figure 2B). Next we analyzed the cellular ef-
fects of argyrin A treatment using a panel of different cell lines. As
shown by flow cytometry, argyrin A exerted two different cellular
phenotypes (Figure 2C). Primary human fibroblasts and A54924 Cancer Cell 14, 23–35, July 2008 ª2008 Elsevier Inc.and HCT116 cells ceased to proliferate, whereas SW480 and
CaCo as well as MCF7 and HeLa cells underwent apoptosis as
shown by a dramatic increase in the sub-G1 phase fraction
(Figure 2C; see also Figure S1A available online).
Argyrin A-Induced Apoptosis in Tumor Cells Requires
the Stabilization of p27kip1
We recently demonstrated that p27kip1 stabilization prevents
progression from adenomatous polyps to invasive intestinal
cancers (Timmerbeul et al., 2006). We therefore tested whether
argyrin A-induced p27kip1 stabilization would be beneficial in
the treatment of human colon cancer cell-derived tumor xeno-
grafts. We first tested whether argyrin A was active in vivo. After
Figure 1. Argyrin A Induces a Decrease in p27kip1 Turnover
(A) Chemical structure of argyrin A.
(B) SW480, HCT116, and HeLa cells were treated with argyrin A to determine
the expression levels of p27kip1 by western blotting at the indicated time
points.
(C) SW480 and HeLa cells were treated with argyrin A or left untreated for 12 hr,
after which cycloheximide was added at a concentration of 25 mg/ml. The
expression levels of p27kip1 were determined at the indicated time points by
western blotting and normalized against actin expression, which was used
as an internal control. The graph shows a quantification of three independent
experiments. Error bars represent SD.
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Pharmacological Targeting of p27kip1intraperitoneal injection of argyrin A, 20S proteasome was iso-
lated from peripheral blood lymphocytes at different time points
after injection. As shown in Figure 3A, argyrin A inhibited all pro-
teasome activities. While the maximum inhibitory activity was
reached between 24 hr and 48 hr postinjection, all activities
returned to baseline levels after 72 hr. Based on this finding,
we injected tumor-bearing mice every 3 days with argyrin A
(0.15 mg/kg body weight). As shown in Figure 3B, argyrin A led
to a significant reduction in the size of the xenotransplanted
tumors used in these experiments. The extent and kinetics of
tumor regression were comparable to or even more pronounced
than that observed in the bortezomib-treated animals. Impor-
tantly, however, we did not observe any signs of discomfort,
weight loss (Figure 3C), or disease in the argyrin A-treated ani-
mals compared to the bortezomib-treated animals. To assay
the extent of proteasome inhibition, the induction of p27kip1,
and the development of apoptotic cell death in primary tumor tis-
sue, we treated tumor-bearing mice with a single dose of argyrin
A or bortezomib and explanted tumors at the indicated time
points thereafter. As shown in Figure 3D, both bortezomib and
argyrin A treatments led to a significant reduction of proteasome
activity in the primary tumor tissue. Importantly, argyrin A treat-
ment resulted in induction of p27kip1 and apoptotic cell death
in more than 60% of all tumor cells (Figures 3E and 3F).
Next we tested whether the stabilization of p27kip1 was
required for the biological functions associated with argyrin A
Figure 2. Argyrin A Inhibits the Proteasome
(A) Purified human erythrocyte-derived 20S
proteasome was incubated with the indicated
amounts of argyrin A or bortezomib, and the cas-
pase-, chymotrypsin-, and trypsin-like protea-
some activities were measured using fluorogenic
peptide substrates specific for the different
catalytic activities.
(B) SW480 and HCT116 cell lines were incubated
with argyrin A. At the indicated time points, cells
were lysed and the expression levels of p53,
p21, Bax, NF-kB, and actin were analyzed by
western blotting.
(C) The indicated cell lines were treated with
argyrin A, and the G1 and sub-G1 fractions were
determined by flow cytometric analysis. IC50
values were determined by MTT cell proliferation
assays using different concentrations of argyrin A.
treatment. To this end, we treated immor-
talized mouse embryonic fibroblasts
(MEFs) from p27kip1 wild-type or knock-
out mice with argyrin A or the proteasome
inhibitor bortezomib and assayed cell-cy-
cle distribution and apoptosis by flow cy-
tometry. Bortezomib treatment induced
apoptosis after 24 hr in both cell lines irre-
spective of p27kip1 status, as measured
by an increase in the sub-G1 fraction
(Figure 4A; Figure S1B). The same re-
sponse was observed with MG132 treat-
ment (data not shown). In strong contrast,
argyrin A treatment induced apoptosis in
cells that expressed p27kip1 while only 10% of p27kip1 knockout
fibroblasts underwent apoptotic cell death after 60 hr of treat-
ment. These differences in sensitivity in response to argyrin A
treatment were not due to differences in the accumulation of other
proteasomal substrates in p27kip1 wild-type and knockout cells,
as p53 and p21 levels increased in both cell lines in response to
argyrin A (Figure 4B). To extend this observation to human cancer
cells, we reduced the levels of p27kip1 in HeLa cells using p27kip1-
specific siRNA. As shown in Figure 4C, HeLa cells expressing
p27kip1 underwent apoptosis in response to argyrin A after 48 hr
of treatment, while cells in which the expression of p27kip1 was
reduced by pretreatment with p27kip1 siRNA were protected
against the apoptosis-inducing function of this compound.
To gain more insight into the molecular mechanism by which
p27kip1 induces apoptosis in response to argyrin A treatment,
we tested whether this process depends on the cyclin kinase in-
hibitory function of the p27kip1 protein. To answer this question,
we used embryonic fibroblasts derived from a p27kip1 knockin
mouse strain that expresses a mutant form of p27kip1 that cannot
bind cyclin/cdk complexes (p27C-K-) (Besson et al., 2007).
Treatment of these cells or wild-type control cells with argyrin
A led to the induction of p27kip1 expression (Figures S1C and
S1D) and apoptosis (Figure 4D). However, suppression of
p27kip1 expression by siRNA pretreatment protected p27C-K-
MEFs against the apoptosis-inducing activity of argyrin A (Fig-
ure 4E). These data indicate that the apoptosis-inducing functionCancer Cell 14, 23–35, July 2008 ª2008 Elsevier Inc. 25
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Pharmacological Targeting of p27kip1Figure 3. Argyrin A Induces Apoptosis in Human Colon Cancer Xenografts In Vivo
(A) Mice were injected intraperitoneally with argyrin A (0.03 mg/kg body weight) or bortezomib (1 mg/kg body weight). At the indicated time points, 20S protea-
some was isolated from peripheral blood cells and the activity of the different proteasome subunits was determined as described in Figure 2A.
(B) SW480 colon carcinoma cell lines mixed with Matrigel were injected under the skin of nu/nu mice to establish xenotransplant tumors. Treatment with argyrin A
or bortezomib was begun when these tumors reached a volume of 200 mm3. The graph shows a quantification of tumor volumes at the indicated time points
compared to the starting size, which was set as 100. n = 8 argyrin A (0.15 mg/kg body weight); n = 4 bortezomib (0.6 mg/kg body weight); n = 10 PBS/EtOH control.
(C) All mice were weighed throughout the course of the experiment. The graph shows the changes in body weight for mice treated with argyrin A versus borte-
zomib.
(D) Determination of proteasome activity in tumor tissue after treatment with bortezomib and argyrin A. After a one-time injection of the respective compounds,
tumors were explanted at the indicated time points and proteasomes were extracted from the tumor tissue. The activity of the respective proteasome subunits
was determined as described in Figure 2A.
(E) Determination of the number of p27kip1-positive cells in tumor tissue after argyrin A treatment. The images show representative samples of immunohistochem-
ical stainings for p27kip1 in tumor tissues after 10 days of argyrin A treatment.
(F) Detection of apoptotic cells in xenotransplanted tumors by TUNEL staining of tumor tissues after treatment with argyrin A or bortezomib. At least 200 cells were
counted on five independent sections to quantitate the number of apoptotic cells.
Error bars in (A)–(D) represent SD. Scale bars in (E) and (F) = 50 mm.26 Cancer Cell 14, 23–35, July 2008 ª2008 Elsevier Inc.
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Pharmacological Targeting of p27kip1Figure 4. Apoptosis Induced by Proteasome Inhibition Depends on the Expression of p27kip1
(A) Mouse embryonic fibroblasts (MEFs) derived from either wild-type (WT) or p27kip1 knockout (KO) mice were treated with argyrin A. The number of apoptotic
cells was determined by measuring the sub-G1 fraction by flow cytometry. Results shown are the average of six independent experiments.
(B) p27kip1 wild-type or knockout MEFs were incubated with argyrin A, and the expression levels of p21, p53, Bax, and actin were determined at the indicated time
points.
(C) HeLa cells were treated with argyrin A, siRNA against p27kip1, or both for either 24 hr (left) or 48 hr (right). The cell-cycle distribution was measured by flow
cytometry. The western blots below show the expression levels for p27kip1 in response to the different treatments.
(D) MEFs derived from p27kip1 wild-type or p27C-K- knockin mice (C-K-) were treated with argyrin A or bortezomib or left untreated. The number of apoptotic cells
was determined by flow cytometry.
(E) p27C-K- MEFs were treated with argyrin A, bortezomib, or siRNA against p27kip1 as indicated. The number of apoptotic cells was determined by flow
cytometry.
(F) Activity of caspase-3 in HeLa cells after treatment with argyrin A, siRNA against caspase-3 (casp3), siRNA against p27kip1, or the indicated combinations,
displayed as % of activity compared to untreated cells.
(G) Western blot analysis of p27kip1, caspase-3, and actin in HeLa cells treated as indicated.
Error bars represent SD.Cancer Cell 14, 23–35, July 2008 ª2008 Elsevier Inc. 27
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Pharmacological Targeting of p27kip1of p27kip1 in response to proteasome inhibition is independent of
its well-characterized function as a cyclin kinase inhibitor.
Proteasome inhibition by argyrin A leads to the stabilization of
several different proteins (Figure 2B) that might be involved in the
induction of apoptosis in an additive or synergistic manner with
p27kip1. Caspase-3, for example, is itself a substrate of the pro-
teasome and a well-known inducer of cell death in response to
proteasome inhibition (Suzuki et al., 2001). We therefore asked
whether caspase-3 activation is required for the argyrin A-in-
duced and p27kip1-mediated induction of cell death. As shown
in Figure 4F, treatment of HeLa cells with argyrin A led to an in-
crease in caspase-3 activity as compared to untreated control
cells. Loss of caspase-3 by siRNA treatment protected cells
against the apoptosis-inducing activity of argyrin A (Figure 4F)
without significantly affecting the levels of p27kip1 (Figure 4G).
Loss of p27kip1 in turn prevented the activation of caspase-3
in response to argyrin A treatment (Figure 4F). This experiment
establishes caspase-3 as a downstream effector of p27kip1-
mediated cell death.
While these results point to a central role of p27kip1 in mediat-
ing the apoptosis-inducing function of argyrin A, they do not ex-
clude the possibility that other proteasome-regulated proteins
exist that might act in parallel to p27kip1. We therefore tested
the importance of IkBa and c-Myc stabilization for the induction
of apoptosis in response to argyrin A treatment. The expression
of both proteins is controlled by proteasome-mediated degrada-
tion, both proteins are regulators of central survival pathways,
and both have also been shown to be involved in the control of
bortezomib-induced cell death (Adams, 2004a, 2004b; Nikiforov
et al., 2007). As shown in Figures S2A and S2B, neither c-Myc
nor IkBa knockdown led to a significant reduction in the number
of apoptotic MCF7 breast cancer cells after argyrin A treatment.
In summary, these results show that the ability of argyrin A to
induce apoptosis in tumor cells depends on the expression of the
tumor suppressor protein p27kip1. Interestingly, this profound
effect is independent of the cyclin kinase inhibitory function of
p27kip1 but involves the activation of caspase-3. While these
data point to a central function of p27kip1 in mediating argyrin
A-induced cell death, they do not exclude the possibility of
parallel independent pathways of equal importance.
Argyrin A-Induced p27kip1 Stabilization Prevents
Neovascularization and Damages Existing
Tumor Blood Vessels
Next we tested whether argyrin A would also show an effect
against HCT116-derived tumor xenografts, as these cell lines
did not undergo apoptosis in vitro but instead arrested in the G1
phase. While the reduction in tumor size was not as pronounced
as in SW480-derived xenotransplants, we still observed a signifi-
cant reduction after treatment with argyrin A (Figure 5A). Interest-
ingly, when SW480- or HCT116-derived tumors were explanted,
they uniformly showed a large necrotic area in the center of the
tumor that was filled with blood and necrotic tumor tissue
(Figure 5B). This phenotype is often observed with drugs that in-
terfere with blood vessel formation or compounds that directly
damage existing tumor vessels (Tozer et al., 2005).
To analyze this phenotype in greater detail, we first asked
whether argyrin A was able to prevent the formation of capil-
lary-like tube structures formed by human umbilical vein endo-28 Cancer Cell 14, 23–35, July 2008 ª2008 Elsevier Inc.thelial cells (HUVECs) on Matrigel, an assay frequently used to
test the ability of a compound to interfere with neovascularization
(Maffucci et al., 2005). Figure 5C shows a quantification of the
relative length of capillary tubes formed by HUVECs upon stim-
ulation with vascular endothelial growth factor (VEGF). The addi-
tion of argyrin A led to a 40% reduction in tube formation in this
assay. We then asked whether, in analogy to the results
observed for the induction of apoptosis in transformed cells, a re-
duction of p27kip1 expression levels would protect endothelial
cells against the inhibitory activity of argyrin A. Indeed, when
HUVECs were transfected with siRNA against p27kip1 before
argyrin A was added, an almost complete rescue of tube length
was observed. The effects exerted by bortezomib in this assay
were smaller and were not rescued by loss of p27kip1. In addition
to tube length, we also quantitated the number of blood vessel-
like structures formed by HUVECs after treatment with argyrin
A or bortezomib (Figure 5D). Both treatments led to a significant
reduction in vessel-like structures. However, loss of p27kip1 only
had a significant effect on the argyrin A-induced phenotype, re-
inforcing the notion that argyrin A exerts its biological functions
through an increase in p27kip1 expression. In line with previous
observations (Roccaro et al., 2006) showing that proteasome
inhibition leads to a reduction in VEGF secretion, we found that
both drugs induced an approximately 40% reduction in the ex-
pression of VEGF by endothelial cells, which was at least partially
rescued by the loss of p27kip1 (Figure 5E). While the reduction in
VEGF levels can contribute to the observed antitumoral effects
in vivo, the relatively strong increase in VEGF secretion after
ablation of p27kip1 by siRNA also suggests that p27kip1 might
control the expression levels of VEGF independently of mech-
anisms affected by proteasome inhibition.
The formation of a necrotic area in the center of a tumor can
also be caused by agents that directly target the preexisting
tumor vasculature. We therefore determined the microvessel
density in tumor tissues (SW480 or HCT116) from mice that
received a single injection of argyrin A. Figure 6A shows that
argyrin A leads to the induction of p27kip1 expression in CD31-
positive endothelial cells as early as 90 min after injection. The
increased expression of p27kip1 correlated with a striking reduc-
tion of cells that stained positive for CD31, with only about 10%
of the positive cells remaining at 72 hr after injection (Figure 6B).
Reduction in CD31 staining can be caused by destruction of the
endothelial cells or by loss of endothelial function. To understand
this phenotype in greater detail, we analyzed primary tumor ma-
terial by electronic microscopy. As early as 90 min after injection,
we observed swelling of endothelial cells that was followed by
a loss of basal membrane attachment and cell-cell contacts (Fig-
ure 6C) at later time points. As a result, many of the examined tu-
mor blood vessels were occluded with endothelial cells or eryth-
rocytes. The destruction of the tumor core that we observed after
argyrin A treatment might therefore be a result of thrombotic oc-
clusion of the affected blood vessels. In contrast, the bortezo-
mib-induced reduction in CD31-positive cells correlated with
the appearance of apoptotic endothelial cells (Figure 6C). While
many vessel-damaging agents exert their effects through a tubu-
lin-stabilizing activity (Tozer et al., 2005), argyrin A interferes with
the ability of the endothelial cell to adhere to the basal mem-
brane. We therefore tested whether argyrin A could also reduce
the ability of cultured endothelial cells to form focal adhesions.
Cancer Cell
Pharmacological Targeting of p27kip1As shown in Figure 6D, staining of human endothelial cells with
paxillin antibodies showed a significant reduction in the number
of focal adhesions in argyrin A-treated cells as compared to un-
treated cultures. The reduction in paxillin staining was accompa-
nied by a reduced formation of stress fibers, which were visual-
ized through staining of cultured endothelial cells with antibodies
specific for actin. Importantly, both the loss of focal adhesions
and the loss of stress fiber formation were reverted when
p27kip1 expression was reduced with p27kip1-specific siRNA
before argyrin A was added to the medium.
Stress fiber formation and expression of focal adhesions are
both processes regulated through activation of RhoA signaling
(Leung et al., 1996; Ridley and Hall, 1992). RhoA activity was
therefore directly measured through the use of antibodies that
detect the Ser3-phosphorylated form of cofilin, a well-character-
ized downstream target of RhoA signaling (Besson et al., 2004).
Figure 6E shows that treatment with argyrin A reduced the
amount of phosphorylated cofilin, while treatment with siRNA
against p27kip1 restores the expression of phosphorylated cofilin
completely.
Previous work (Read et al., 1995) had shown that proteasome
inhibition due to a reduction in NF-kB activity can also affect in-
Figure 5. Argyrin A Damages Existing
Tumor Blood Vessels and Interferes with
Neovascularization in a p27kip1-Dependent
Manner
(A) HCT116 colon carcinoma cell lines mixed with
Matrigel were injected under the skin of nu/nu
mice to establish xenotransplant tumors. Treat-
ment with argyrin A or bortezomib was begun
when these tumors reached a volume of 200
mm3. The graph shows a quantification of tumor
volumes at the indicated time points compared
to the starting size, which was set as 100. n = 8
argyrin A; n = 8 bortezomib; n = 6 PBS/EtOH.
(B) Macroscopic appearance of a xenotransplant
tumor after 10 days of treatment with argyrin A.
Note the large necrotic center of the explanted
tumor (right).
(C and D) Human umbilical vein endothelial cells
(HUVECs) were grown in endothelial cell basal me-
dium supplemented with growth factors and con-
taining 2% FCS for 24 hr and treated with argyrin A
(1 mM), bortezomib (10 nM), siRNA against p27kip1,
argyrin A and siRNA, or bortezomib and siRNA.
Tube length (C) and blood vessel-like structures
(D) were determined using photographs of HUVEC
cultures. The micrographs show representative
examples of HUVEC cultures under the indicated
conditions. Scale bars = 100 mm.
(E) Expression levels of vascular endothelial
growth factor (VEGF) in human endothelial cells
after treatment with argyrin A, bortezomib, siRNA
against p27kip1, or the indicated combinations.
Error bars represent SD.
tegrinsignaling,which results ina reduced
expression of vascular cell adhesion mol-
ecule-1 (VCAM-1) and intercellular adhe-
sion molecule-1 (ICAM-1). As shown in
Figures S3A and S3B, treatment of HU-
VECs with argyrin A or bortezomib led to a reduction in VCAM-
1 and ICAM-1 expression, a process that was rescued by the
siRNA-mediated suppression of IkBa expression. Interestingly,
however, the expression of these proteins was still reduced in ar-
gyrin A-treated cells in which p27kip1 expression was reduced by
siRNA (Figures S3C and S3D). These results indicate that the loss
of p27kip1 is sufficient to rescue argyrin A-induced changes in cell
adhesion despite the inactivation of other central signaling path-
ways. We conclude that argyrin A exerts its effects on preexisting
blood vessels through the stabilization of p27kip1 in endothelial
cells, which correlates with an inhibition of RhoA signaling.
Loss of RhoA signaling induces reduced formation of stress fi-
bers, a reduction in the phosphorylation of downstream effectors,
and reduced formation of focal adhesions. These molecular
changes provide an explanation for the occlusion of tumor blood
vessels in vivo, which resulted in complete destruction of the core
of the tumor.
p27kip1 Is a Critical Downstream Target
of the Proteasome
At this point of our analysis, we had found that argyrin A
exerts different antitumoral activities. It induces apoptosis inCancer Cell 14, 23–35, July 2008 ª2008 Elsevier Inc. 29
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Pharmacological Targeting of p27kip1transformed cells, prevents neovascularization, and leads to
a loss of adherence of tumor endothelial cells. All of these activ-
ities depend on the expression of p27kip1, while loss of this pro-
tein confers resistance to argyrin A treatment. Nevertheless, we
found the molecular mechanism by which argyrin A exerts its
p27kip1-stabilizing activity to be the inhibition of the 20S protea-
some, a multiprotein complex that is involved in the destruction
of the majority of all cellular proteins. Moreover, the well-known
and clinically used proteasome inhibitor bortezomib showed no
specificity for p27kip1 and also differed in its in vitro and in vivo
activities from those observed with argyrin A.
We therefore decided to directly test the extent to which the
cellular effects of proteasome inhibition per se are influenced
by p27kip1 expression. To this end, we designed specific siRNA
molecules that target the b1 (caspase-like activity), b2 (trypsin-
like activity), and b5 (chymotrypsin-like activity) subunits of the
mouse 20S proteasome. We then reduced the expression of
these subunits in embryonic fibroblasts derived from wild-type
or p27kip1 knockout cells and measured proteasome activity
and cell-cycle distribution. Figures 7A and 7C show activity
measurements for the caspase-, chymotrypsin-, and trypsin-
like activities of the proteasome after treatment with argyrin A
or a combination of siRNAs against the b1, b2, and b5 subunits
inp27kip1 wild-type or knockout cell lines. Importantly, the degree
Figure 6. Argyrin A Damages the Existing
Tumor Blood Vessels
(A) After a single injection of argyrin A (0.15 mg/kg
body weight) or bortezomib (1.0 mg/kg body
weight), tumors were explanted at the indicated
time points and blood vessels in the tumor tissue
were costained for CD31 (red) and p27kip1 (green).
Scale bars = 25 mm.
(B) Quantification of the data in (A). Error bars
represent SD.
(C) The ultrastructure of microvessels was ana-
lyzed after injection of argyrin A (left and middle
image) or bortezomib (right image), respectively.
Note the swelling of the endothelial cell (E) and
the occlusion of the lumen (L) by erythrocytes after
90 min of argyrin A treatment. The black arrow
marks the detachment of endothelial cells after
48 hr of argyrin A treatment. The right panel shows
apoptotic endothelial cells after treatment with
bortezomib.
(D) HUVECs were treated with control siRNA,
argyrin A, or argyrin A and siRNA against p27kip1
as indicated. The cells were fixed and stained
with antibodies against paxillin or actin. Scale
bars = 25 mm.
(E) HUVECs were treated as indicated, and protein
samples were analyzed by western blotting for ex-
pression of phosphorylated cofilin. Actin was used
as a control.
of proteasome inhibition we achieved
with siRNA-mediated knockdown of pro-
teasomal subunits was comparable to
the effects exerted by argyrin A or borte-
zomib treatment in vivo (cf. Figure 3A).
The levels of proteasome subunit expres-
sion are displayed in the corresponding western blots.
Loss of proteasome activity in wild-type fibroblasts led to the
induction of apoptosis in approximately 35% (argyrin A) or 45%
(siRNA) of all cells after 24 hr (Figure 7B). Importantly, only 5%
(argyrin A) or 6% (siRNA) of all fibroblasts derived from p27kip1
knockout mice underwent apoptosis at comparable levels of
proteasome inhibition (Figure 7D), while treatment of wild-type or
p27kip1 knockout cells with bortezomib induced massive apopto-
sis independent of p27kip1 status (cf. Figure 4A). These results
point towardanasyet unrecognized roleof p27kip1 asa critical reg-
ulator of apoptotic cell death in response to proteasome inhibition.
To understand in greater detail the mechanisms that make ar-
gyrin A-induced cell death dependent upon p27kip1 expression,
we decided to compare the cellular responses of cells treated
with argyrin A versus bortezomib directly. One way to obtain in-
formation on the reaction of a cell toward an external perturba-
tion is to determine the gene expression signature of that cell
in response to the perturbation (Lamb et al., 2006). To this end,
we determined the gene expression signatures of MCF7 cells
in response to argyrin A, bortezomib, or b1,2,5 siRNA and com-
pared the resulting gene expression profiles. Figure 7E shows
a Pearson correlation plot of the gene expression data that we
obtained in these experiments using untreated or argyrin
A-, bortezomib-, or siRNA-treated MCF7 cells. Figure S4A shows
30 Cancer Cell 14, 23–35, July 2008 ª2008 Elsevier Inc.
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(A and C) Wild-type (A) and p27kip1 knockout (C) MEFs were treated with argyrin A or transfected with siRNAs specific for the b1, b2, or b5 subunit of the pro-
teasome for 24 hr. Graphs show the remaining catalytic activity of the different proteasome subunits after argyrin A or siRNA treatment compared to an untreated
control (n = 3). Western blots below show the expression of the b1, b2, or b5 subunit of the proteasome in proliferating cells before and after treatment with siRNAs
for a representative experiment.
(B and D) Flow cytometric measurements of the number of apoptotic cells (sub-G1 fraction) after argyrin A or siRNA treatment in wild-type (B) or p27kip1 knockout
(D) MEFs.
(E) Heat map displaying a correlation analysis of genome-wide gene expression profiles of MCF7 breast cancer cells treated with argyrin A, bortezomib, or siRNA
against the b1,2,5 subunits of the proteasome for the indicated amounts of time. The corresponding correlation value matrix is given in Figure S4B.
(F) Number of apoptotic MCF7 cells after transfection with siRNA specific for the b1,2,5 subunits of the proteasome or combined treatment with siRNA and argyrin
A or bortezomib. The corresponding proteasome activity measurements are given in Figures S4D and S4E.the corresponding proteasome activity measurements in MCF7
cells, and Figure S4C shows the correlation values. As shown
in Figure 7E, the gene expression profiles of MCF7 cells treated
with bortezomib versus argyrin A differ dramatically. While borte-
zomib treatment led to changes in the expression of more than
10,900 genes (Table S1), only about 500 genes (Table S2)changed in response to argyrin A treatment. Among these genes,
311 were affected by both bortezomib and argyrin A. The func-
tional gene clustering based on their corresponding gene ontol-
ogy terms (Tables S3A–S3C) indicates that while argyrin A and
bortezomib both inhibit the 20S proteasome, they cause very
divergent perturbations at the cellular level. From these data,Cancer Cell 14, 23–35, July 2008 ª2008 Elsevier Inc. 31
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gets in the cell that result in the activation of various cellular re-
sponses that make bortezomib-induced cell death independent
of p27kip1 expression. In a second set of experiments, we com-
pared the gene expression profiles of argyrin A- and siRNA-me-
diated knockdown of proteasome subunits at comparable levels
of proteasome inhibition (Figures S4B and S5; Table S7). These
experiments revealed that siRNA-mediated proteasome inhibi-
tion, like argyrin A treatment, led to very limited alterations in
the gene expression profiles of MCF7 cells (Tables S4 and S5),
with approximately 30% of the regulated genes overlapping be-
tween argyrin A- and siRNA-treated cells (Figure S6; Table S6).
This result indicates that both types of treatment result in few
off-target effects. The limited degree of overlap between siRNA-
and argyrin A-treated cells may reflect the differences in acute in-
hibition of proteasome activity by a chemical compound as com-
pared to the reduction in proteasome subunit transcription by
siRNA treatment. Our gene expression studies also revealed
no evidence for the expression of gene sets associated with
the activation of the ER-stress response that has been observed
in cells treated with bortezomib (Obeng et al., 2006) (Figure S7).
Finally, we decided to directly test whether the biological activ-
ities we observed with argyrin A and bortezomib are at least in
part independent of their ability to inhibit the proteasome. To an-
swer this question experimentally, we compared the effects of
bortezomib and argyrin A treatment in MCF7 breast cancer cells
with cells in which the activity of the proteasome had first been
reduced by siRNA-mediated knockdown of the b1, b2, and b5
subunits and which were then treated with argyrin A or bortezo-
mib. Figure 7F shows that argyrin A treatment of cells with re-
duced proteasome activity did not lead to a significant increase
in proteasome inhibition (cf. Figures S4D and S4E for proteasome
activity measurements) or in the number of apoptotic cells. Addi-
tion of bortezomib to MCF7 cells with reduced proteasome activ-
ity also did not increase the level of proteasome inhibition but did
result in a >50% increase in the number of apoptotic cells as
compared to ‘‘pure’’ proteasome inhibition. These data support
the conclusion that bortezomib has cellular effects other than
proteasome inhibition that contribute to its biological function.
DISCUSSION
Using a combination of in vitro and in vivo studies, we define
three mechanisms by which argyrin A influences tumor cell pro-
liferation, all of which depend on the stabilization of p27kip1. By
inducing apoptosis, argyrin A can target the tumor cell itself. Pre-
vious work pointed to an apoptosis-inducing function of p27kip1
overexpression in tumor cells (Katayose et al., 1997; Katner
et al., 2002; Wang et al., 1997; Zhang et al., 2005); however,
the molecular mechanism by which p27kip1 causes cell death
is largely unknown. Gene expression profiles of argyrin A-treated
MCF7 cells revealed the induction of genes that are involved
in the release of cytochrome c from the mitochondria, pointing
toward a role of the endogenous apoptosis pathway (Table S3A).
Importantly, however, the apoptosis-inducing function of argyrin
A was entirely dependent on the expression of p27kip1, as neither
cells derived from p27kip1 knockout mice nor cells in which
p27kip1 expression was abolished through siRNA responded to
the compound. Nevertheless, p27kip1 does not induce apoptosis32 Cancer Cell 14, 23–35, July 2008 ª2008 Elsevier Inc.directly but requires the activation of downstream effectors such
as caspase-3. The molecular mechanism by which p27kip1 ex-
erts this function is unknown. Surprisingly, however, it does not
involve its cyclin kinase inhibitory activity, as cells expressing
a non-cdk-binding version of the protein still undergo cell death
when treated with argyrin A. This observation is not without
precedence, however, as the cyclin kinase inhibitor p57kip2
was recently shown to promote apoptosis by activating the in-
trinsic pathway in response to chemotherapies independently
of its cyclin kinase inhibitory function (Vlachos et al., 2007). Our
observations therefore add to a growing body of evidence attrib-
uting additional functions to the p27kip1 protein that are not reg-
ulated by the classical cyclin kinase inhibitory activity (Besson
et al., 2007; Nguyen et al., 2006; Vernon and Philpott, 2003).
Not all tumor cells that were treated with argyrin A in vitro un-
derwent apoptosis; some instead ceased to proliferate and un-
derwent cell-cycle arrest. A reduction in the proliferative fraction
of a tumor is not necessarily beneficial, as quiescent cells are
often resistant to chemotherapy or radiation treatment. We
therefore tested the extent to which xenotransplanted tumors
derived from cells that underwent G1 arrest in response to ar-
gyrin A in vitro would still be sensitive to the compound in vivo.
We found that such tumors could also be effectively treated.
The most prominent change in the tumor tissue was a complete
destruction of the core of the cancer, pointing toward an antian-
giogenic or vessel-damaging effect of argyrin A. In agreement
with previous studies showing that overexpression of p27kip1
in human endothelial cells through adenoviral gene transfer re-
duces cell proliferation (Goukassian et al., 2001), we found that
argyrin A reduced the ability of such cells to form vessel-like
structures and also reduced the expression of VEGF. This
activity was again dependent on the expression of p27kip1, as
siRNA-transfected endothelial cells became resistant toward
treatment with argyrin A and restored VEGF expression.
The third and most surprising antitumoral function of argyrin A
is its ability to target preexisting tumor vessels directly. By study-
ing the ultrastructural properties of argyrin A-treated tumors, we
found that a single injection of argyrin A induced a loss of adher-
ence of endothelial cells from the basal membrane, which re-
sulted in a protrusion of these cells into the lumen of the vessels.
Loss of endothelial cell adhesion was accompanied by signs of
thrombosis of the affected tumor vessels. In agreement with
these observations in tumor tissues, we found that argyrin A re-
duces the number of focal adhesions in endothelial cells in vitro
by interfering with the activity of RhoA signaling. The role of RhoA
in cellular adhesion has been extensively studied, and it was re-
cently shown that p27kip1 can control RhoA signaling directly
(Besson et al., 2004). p27kip1 knockout cells show increased
levels of RhoA activity, while re-expression of p27kip1 inhibits
downstream signaling and influences cellular functions like cell
migration or adhesion. In line with these observations, we found
that the ability of argyrin A to block RhoA signaling and thereby
cell adhesion depends on the expression of p27kip1. Loss of
p27kip1 prevents RhoA inhibition by argyrin A and results in the
preservation of focal adhesion and stress fiber formation.
Together, these findings show that argyrin A exerts its antitu-
moral activities through the stabilization of p27kip1. This observa-
tion is surprising given that our studies indicate that the mecha-
nism by which argyrin A prevents p27kip1 turnover is through the
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proteasome inhibitory activity of argyrin A was demonstrated
on purified proteasomes in vitro, in peripheral blood cells
in vivo, and in proteasome derived from tumor tissue itself. It en-
compasses all catalytic activities and is not specific for p27kip1,
as a number of other proteasomal substrates like p21, p53,
and others are no longer degraded in cells treated with argyrin A.
Surprisingly, by blocking proteasome activity with siRNA di-
rected against catalytic proteasomal subunits, we found that
p27kip1 is indeed required for the apoptosis-inducing function
of proteasome inhibition per se. While the proteasome is
involved in the regulation of the majority of cellular proteins,
our observations regarding the critical role of p27kip1 imply that
some proteasomal substrates are of key importance in mediat-
ing the biological effects connected with proteasome inhibition;
one such key substrate is p27kip1. The identification of one key
proteasome target leads us to speculate that other proteins of
equal importance must exist that in an either additive or syner-
gistic manner cause the different biological effects connected
with proteasome inhibition.
Our data show that the specificity of argyrin A for p27kip1 is not
sharedby the proteasome inhibitor bortezomib.Bycomparing the
gene expression patterns of argyrin A- and bortezomib-treated
cells, we found that the cellular responses exerted by these treat-
ments are highly divergent. Specifically, we found that bortezo-
mib affects a multitude of additional cellular targets that result in
a broader biological response of the treated cell. In fact, bortezo-
mib treatment of cells in which the proteasome was partly in-
hibited through siRNA-mediated reduction in proteasome subunit
expression still responded with an increase in the number of apo-
ptotic cells without a further reduction in proteasome activity. In
strong contrast, argyrin A- and siRNA-mediated reduction in pro-
teasome activity resulted in only very limited changes in gene ex-
pression profiles. The activity and toxicity profile of clinically used
inhibitors like bortezomib might therefore not result entirely from
the inhibition of the proteasome but may reflect the disruption of
additional cellular systems such as the induction of endoplasmic
reticulum stress (Obeng et al., 2006). Given that proteasome in-
hibitors have been shown to synergize with a number of chemo-
therapeutic or molecular drugs in vitro, it will be important to
test whether the greater specificity of argyrin A will allow higher
levels of proteasome inhibition at a tolerable level of toxicity.
In summary, we have identified argyrin A as a proteasome
inhibitor that by preventing the destruction of the cyclin kinase
inhibitor p27kip1 exerts broad antitumoral activities. Second, we
found that stabilization of p27kip1 in addition to targeting the tumor
cell itself also affects the tumor vasculature through p27kip1-medi-
ated inhibition of RhoA activity. And lastly, we found that p27kip1
belongs to a group of critical proteasomal substrates that are
responsible for the biological phenotypes induced under condi-
tions of proteasome inhibition. The unique properties of argyrin
A combined with its high activity at well-tolerated levels make
this compound a good candidate for further clinical development.
EXPERIMENTAL PROCEDURES
High-Throughput Screen for p27kip1-Stabilizing Substances
A cellular high-throughput screen for p27kip1-stabilizing compounds was
established by stably introducing a DNA plasmid (EGFP-N1, Clontech) thatallows the expression of p27kip1-GFP fusion protein in HeLa cells. p27kip1-
GFP-expressing cells were selected with neomycin, and several independent
clones were subcultured. HeLa p27kip1-GFP cells were seeded in 384-well
plates (Corning) and incubated with a set of highly diverse natural products
(part of the Helmholtz Center for Infection Research myxobacterial metabolite
collection) at a concentration of 70 nM. GFP emission was determined by fluo-
rometric measurements using a Victor 1420 multilabel counter (PerkinElmer) at
3 hr, 24 hr, 48 hr, and 60 hr after the start of treatment. The proteasome inhib-
itor MG132 was used as a positive control. All compounds used for high-
throughput screening were dissolved in DMSO at a concentration of 1 mM
in 96-well polypropylene microtiter plates. The Helmholtz Center for Infection
Research collection of myxobacterial metabolites (Reichenbach and Ho¨fle,
1999) contained 120 pure compounds (>95% pure).
Antibodies, Western Blotting, Immunofluorescence,
and Immunohistochemistry
Immunohistochemical staining of mouse tumor tissue, western blotting, cdk2-
associated kinase activity measurements, and immunofluorescence experi-
ments were performed as described previously (Kossatz et al., 2006; Timmer-
beul et al., 2006). For antibodies used in this study, refer to the Supplemental
Data.
siRNA
siRNA knockdown was performed using FuGENE6 or HiPerFect transfection
reagent. Transfections were performed using siRNA in a concentration of
0.2 nM for Psmb1, Psmb2, PSMB1, PSMB2, CDKN1B, CASP3, NFKBIA,
MYC, and p27kip1 and in a concentration of 0.4 nM for Psmb5 and PSMB5.
Proteasome Purification and Proteasome Assays
Proteasome assays with purified 20S proteasome were performed as
described previously (Lightcap et al., 2000) using erythrocyte-derived 20S pro-
teasome (Biomol International, LP PW8720) and the fluorometric substrates
Succ-LLVY-AMC, BZ-VGR-AMC, and Z-Lle-AMC (Biomol International, LP
PW9905). Proteasome extraction from cells and tumor sections was per-
formed as described previously (Crawford et al., 2006). For proteasome ex-
traction from whole blood, frozen whole blood cell pellets were thawed and
lysed in 2–3 pellet volumes of cold lysis buffer (5 mM EDTA [pH 8.0]). Lysates
were spun down at 4C, and the supernatant was transferred to a fresh tube.
Five microliters was taken for the determination of protein concentration using
a Coomassie protein assay (Pierce). Proteasome assays using proteasome
purified from cells or tissues were carried out in a 100 ml reaction volume con-
taining 20 mg proteasome extract, 50 mmol/l EDTA, and 60 mmol/l fluorogenic
substrate (chymotrypsin-like [CT-L], trypsin-like [T-L], or caspase-like [C-L]) in
ATP/DTT lysis buffer at 37C. The assay buffer was supplemented with a final
concentration of 0.05% SDS for the evaluation of the chymotrypsin-like activ-
ity and caspase-like activity. The rate of cleavage of fluorogenic peptide sub-
strates was determined by monitoring the fluorescence of released aminome-
thylcoumarin using a Victor 1420 multilabel counter (Wallac) at an excitation
wavelength of 395 nm and emission wavelength of 460 nm over a period of
60 min.
Xenotransplant Studies
All experiments were performed after review by and in accordance with the
animal rights and protection agencies of Lower Saxony, Germany. 1 3107
SW480 cells or HCT116 cells in 100 ml DMEM medium and 100 ml Matrigel
were subcutaneously injected into the flanks of NMRI nu/nu mice. Tumors
grew for approximately 18 days until they reached an appropriate size
(200 mm3). Tumor size was measured with a digital caliper and calculated
with the help of the following formula: (length 3 [width2]) 3 p/6.
Electronic Microscopy
Small specimens of tumor were fixed in 2.5% glutaraldehyde (Polysciences) in
0.1 M sodium cacodylate (pH 7.3) and postfixed with 2% osmium tetroxide
(Polysciences) in the same buffer. After dehydration in graded alcohols,
specimens were embedded in Epon (Serva). Thin sections stained with uranyl
acetate and lead citrate were examined in a Philips EM 301 electron micro-
scope. The electron micrographs were selected, digitalized, and processed
using Adobe Photoshop 6.0.Cancer Cell 14, 23–35, July 2008 ª2008 Elsevier Inc. 33
Cancer Cell
Pharmacological Targeting of p27kip1DNA Microarray Hybridization and Analysis
DNA microarray hybridization was performed as described previously (Pfoert-
ner et al., 2006). For details on data analysis, please refer to Supplemental
Experimental Procedures.
Statistical Analysis
Statistical analysis was carried out using Microsoft Excel software. Unless
stated otherwise, all data are presented as mean ± SD; error bars represent
SD in all figures. Intergroup comparisons were performed by two-tailed
Student’s t test. p < 0.05 was considered statistical significant.
ACCESSION NUMBERS
The complete data set is deposited in MIAME-compliant format at the NCBI
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/projects/geo/) and
is available under the accession number GSE8565.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures,
seven figures, and seven tables and can be found with this article online at
http://www.cancercell.org/cgi/content/full/14/1/23/DC1/.
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